Floatz Rating
B60/100
Confidence
Indicative
Sponsor
InSilico Medicine Hong Kong Limited
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07302347CT.gov A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) | — | Recruiting | — | — | — |
NCT06724042CT.gov Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07287995CT.gov A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors | — | Recruiting | — | — | — |
NCT07410676CT.gov EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07262619CT.gov EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | — | Recruiting | — | — | — |
NCT07307053CT.gov Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | — | Not Yet Recruiting | — | — | — |
NCT07252739CT.gov KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | — | Recruiting | — | — | — |
NCT07247110CT.gov A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | — | Recruiting | — | — | — |
NCT07218003CT.gov A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | — | Enrolling By Invitation | — | — | — |
NCT07215637CT.gov Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
Show 156 more trialsShow fewer
NCT07231458CT.gov A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies | — | Recruiting | — | — | — |
NCT07166601CT.gov M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07182591CT.gov A Study of DS5361b in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07197827CT.gov A Study of YL242 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06963814CT.gov Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06719362CT.gov A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies | — | Recruiting | — | — | — |
NCT06682806CT.gov A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | — | Terminated | — | — | — |
NCT06894771CT.gov A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) | — | Completed | — | — | — |
NCT06795412CT.gov Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06880549CT.gov A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06824792CT.gov Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System | — | Not Yet Recruiting | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06561685CT.gov A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06480552CT.gov An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06470763CT.gov A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | — | Active Not Recruiting | — | — | — |
NCT06302426CT.gov Trial of INI-4001 in Patients With Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT06249048CT.gov Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | — | Recruiting | — | — | — |
NCT06384352CT.gov A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06228326CT.gov A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | — | Recruiting | — | — | — |
NCT06328673CT.gov A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05872867CT.gov Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | — | Unknown | — | — | — |
NCT06131398CT.gov A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06004245CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06188208CT.gov A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | — | Terminated | — | — | — |
NCT05761223CT.gov A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | — | Recruiting | — | — | — |
NCT06035744CT.gov CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT06108050CT.gov JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05901285CT.gov Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05970497CT.gov A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05877430CT.gov Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | — | Recruiting | — | — | — |
NCT05978102CT.gov A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05954312CT.gov A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05853367CT.gov Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | — | Recruiting | — | — | — |
NCT05838768CT.gov Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | — | Active Not Recruiting | — | — | — |
NCT05491083CT.gov Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05859074CT.gov A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | — | Recruiting | — | — | — |
NCT05782361CT.gov POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC | — | Active Not Recruiting | — | — | — |
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
NCT05708950CT.gov A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | — | Completed | — | — | — |
NCT05647954CT.gov A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver | — | Unknown | — | — | — |
NCT05614102CT.gov A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05585320CT.gov A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05547321CT.gov Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. | — | Recruiting | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05537740CT.gov A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05508100CT.gov Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors | — | Completed | — | — | — |
NCT05378425CT.gov A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | — | Active Not Recruiting | — | — | — |
NCT05533697CT.gov Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05394103CT.gov Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04605614CT.gov 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | — | Withdrawn | — | — | — |
NCT05438329CT.gov First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05270213CT.gov Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05394350CT.gov A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) | — | Terminated | — | — | — |
NCT05878691CT.gov A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | — | Active Not Recruiting | — | — | — |
NCT05479812CT.gov Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05359445CT.gov IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | — | Active Not Recruiting | — | — | — |
NCT04964960CT.gov Pembro+Chemo in Brain Mets | — | Terminated | — | — | — |
NCT05346484CT.gov A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05120596CT.gov First in Human Study of T3P-Y058-739 (T3P) | — | Recruiting | — | — | — |
NCT05320588CT.gov A Study in Patients With Advanced Cancers | — | Recruiting | — | — | — |
NCT05082259CT.gov ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab | — | Recruiting | — | — | — |
NCT05296772CT.gov Phase 1 First-in-human Study of JS014 | — | Unknown | — | — | — |
NCT05082610CT.gov A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT05098132CT.gov Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers | — | Recruiting | — | — | — |
NCT05081609CT.gov A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT05067283CT.gov A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | — | Recruiting | — | — | — |
NCT04837196CT.gov Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | — | Completed | — | — | — |
NCT05117476CT.gov A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05083481CT.gov A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | — | Terminated | — | — | — |
NCT05060432CT.gov Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04999202CT.gov A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults | — | Terminated | — | — | — |
NCT05086692CT.gov A Beta-only IL-2 ImmunoTherapY Study | — | Recruiting | — | — | — |
NCT04976634CT.gov Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | — | Active Not Recruiting | — | — | — |
NCT04787042CT.gov Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | — | Recruiting | — | — | — |
NCT04977453CT.gov GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04920383CT.gov ALPN-202 With PD-1 Inhibition in Advanced Malignancies | — | Terminated | — | — | — |
NCT04659629CT.gov NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | — | Completed | — | — | — |
NCT04859777CT.gov A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | — | Unknown | — | — | — |
NCT04855435CT.gov Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT04717375CT.gov Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04799054CT.gov A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT04752826CT.gov BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | — | Recruiting | — | — | — |
NCT04609579CT.gov Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | — | Terminated | — | — | — |
NCT04682431CT.gov A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04691375CT.gov A Study of PY314 in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04592653CT.gov Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) | — | Active Not Recruiting | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT04555837CT.gov Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | — | Completed | — | — | — |
NCT04513067CT.gov A Safety Study of YQ23 in Advanced Solid Tumors Patients | — | Terminated | — | — | — |
NCT04421560CT.gov Pembrolizumab, Ibrutinib and Rituximab in PCNSL | — | Recruiting | — | — | — |
NCT04561362CT.gov Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | — | Active Not Recruiting | — | — | — |
NCT04485013CT.gov TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | — | Recruiting | — | — | — |
NCT04274907CT.gov A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression | — | Terminated | — | — | — |
NCT04443088CT.gov An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04383938CT.gov Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | — | Completed | — | — | — |
NCT04332653CT.gov NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04348916CT.gov Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | — | Terminated | — | — | — |
NCT04374877CT.gov Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03993353CT.gov Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | — | Completed | — | — | — |
NCT04333004CT.gov Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy | — | Unknown | — | — | — |
NCT04354246CT.gov COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | — | Completed | — | — | — |
NCT04336098CT.gov Study of SRF617 in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04225117CT.gov A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | — | Active Not Recruiting | — | — | — |
NCT04205227CT.gov ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04148937CT.gov A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | — | Completed | — | — | — |
NCT04185883CT.gov Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | — | Active Not Recruiting | — | — | — |
NCT04158700CT.gov A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | — | Withdrawn | — | — | — |
NCT04016116CT.gov Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | — | Withdrawn | — | — | — |
NCT04095273CT.gov Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | — | Completed | — | — | — |
NCT03954067CT.gov A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03941262CT.gov Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | — | Completed | — | — | — |
NCT03829254CT.gov A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | — | Recruiting | — | — | — |
NCT03922204CT.gov A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | — | Completed | — | — | — |
NCT03861793CT.gov A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | — | Completed | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03797326CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | — | Completed | — | — | — |
NCT03589339CT.gov NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | — | Active Not Recruiting | — | — | — |
NCT03785249CT.gov Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | — | Active Not Recruiting | — | — | — |
NCT03799003CT.gov A Study of ASP1951 in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03739138CT.gov Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) | — | Terminated | — | — | — |
NCT04074759CT.gov FPT155 in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03674567CT.gov Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab | — | Completed | — | — | — |
NCT03666273CT.gov Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. | — | Completed | — | — | — |
NCT03568058CT.gov Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | — | Completed | — | — | — |
NCT03565445CT.gov A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03407976CT.gov Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | — | Terminated | — | — | — |
NCT03239145CT.gov Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | — | Completed | — | — | — |
NCT03514121CT.gov FPA150 in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03383094CT.gov Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT03029403CT.gov Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
NCT03277352CT.gov INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | — | Terminated | — | — | — |
NCT03172819CT.gov Special Combination of OBP-301 and Pembrolizumab | — | Completed | — | — | — |
NCT03260322CT.gov A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03179436CT.gov Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | — | Completed | — | — | — |
NCT02959437CT.gov Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | — | Terminated | — | — | — |
NCT03013218CT.gov A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | — | Completed | — | — | — |
NCT02799095CT.gov A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors | — | Completed | — | — | — |
NCT02880371CT.gov A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02904226CT.gov JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | — | Completed | — | — | — |
NCT02843204CT.gov Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | — | Completed | — | — | — |
NCT02828098CT.gov Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors | — | Completed | — | — | — |
NCT02644369CT.gov Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02546531CT.gov Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | — | Completed | — | — | — |
NCT02628067CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | — | Active Not Recruiting | — | — | — |
NCT02553499CT.gov Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) | — | Terminated | — | — | — |
NCT02444741CT.gov Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02325557CT.gov ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) | — | Completed | — | — | — |
NCT02306850CT.gov Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | — | Completed | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
NCT01986426CT.gov LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | — | Completed | — | — | — |
NCT01848834CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | InSilico Medicine Hong Kong Limited | Approved | B · 60 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →